SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-177000
Filing Date
2024-07-10
Accepted
2024-07-10 07:09:00
Documents
13
Period of Report
2024-07-09
Items
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 8-K d853448d8k.htm   iXBRL 8-K 25564
  Complete submission text file 0001193125-24-177000.txt   143907

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amlx-20240709.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20240709_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20240709_pre.xml EX-101.PRE 10810
15 EXTRACTED XBRL INSTANCE DOCUMENT d853448d8k_htm.xml XML 3505
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 241108672
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)